← Eichor
Study identifier: NCT06659549 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Condition: Geographic Atrophy of the Macula  ·  Sponsor: Galimedix Therapeutics Inc

PhasePhase 2
Planned participants110
Who can joinAll sexes, 55 Years to no upper limit
Healthy volunteersNo

About this study

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.

This description comes directly from the study's public registry record.

Talk to the study team

Galimedix Inc. c/o Imperial CRS, MD  ·  +1 (301) 9179191  ·  info@galimedix.com

Luciana Summo, PhD  ·  info@galimedix.com

Always discuss trial participation with your own doctor first.

Locations (14)

Retina-Vitreous Associates Medical GroupBeverly Hills, California, United StatesRecruiting
Bay Area Retina AssociatesWalnut Creek, California, United StatesRecruiting
Cumberland Valley Retina ConsultantsHagerstown, Maryland, United StatesRecruiting
Ophthalmological Center After S.V. MalayanYerevan, ArmeniaRecruiting
Centre Monticelli Paradis d'OphtalmologieMarseille, FranceRecruiting
Akhali Mzera LimitedTbilisi, GeorgiaRecruiting
Caucasus Medical Centre LLCTbilisi, GeorgiaRecruiting
Chichua Medical Centre Mzera LLCTbilisi, GeorgiaRecruiting
Universitäts-Augenklinik BonnBonn, GermanyRecruiting
Institute of Eye Surgery (IOES Waterford)Waterford, IrelandRecruiting
Hadassah Medical CenterJerusalem, IsraelRecruiting
Tel Aviv Medical CenterTel Aviv, IsraelRecruiting

+ 2 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06659549